Black Titan Corp (NASDAQ:BTTC) Short Interest Update

Black Titan Corp (NASDAQ:BTTC) saw a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 49,987 shares, a decrease of 35.7% from the June 30th total of 77,733 shares. Based on an average daily volume of 74,298 shares, the short-interest ratio is presently 0.7 days. Currently, 1.0% of the shares of the stock are sold short.

Black Titan Price Performance

Black Titan stock opened at $0.72 on Friday. The stock’s 50 day moving average is $0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.62 and a quick ratio of 4.62. The company has a market cap of $7.79 million, a P/E ratio of -0.25 and a beta of 1.21. Black Titan has a one year low of $0.64 and a one year high of $39.00.

Black Titan (NASDAQ:BTTC) last released its quarterly earnings data on Friday, June 12th. The company reported ($0.22) earnings per share (EPS) for the quarter. The business had revenue of $0.59 million during the quarter.

Institutional Investors Weigh In On Black Titan

Several large investors have recently made changes to their positions in the company. Marex Group plc acquired a new stake in shares of Black Titan during the 4th quarter worth about $84,000. Renaissance Technologies LLC acquired a new position in Black Titan in the fourth quarter valued at about $26,000. HRT Financial LP acquired a new position in Black Titan in the fourth quarter valued at about $28,000. Finally, Armistice Capital LLC bought a new stake in Black Titan during the fourth quarter worth about $840,000.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.